BioCentury | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

...the study are due this half. Vir began a Phase I/II study last month of anti-influenza mAb...
BioCentury | Nov 2, 2017
Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...
BioCentury | Aug 8, 2016
Emerging Company Profile

Interrogating immunity

...to generate broadly neutralizing HIV antibodies and its Phase II mAb Human anti-M23 antibody ( TCN-032...
BioCentury | Aug 13, 2015
Distillery Therapeutics

Therapeutics: Dengue virus envelope protein E (DENV_gp1)

Infectious disease INDICATION: Dengue fever; viral infection Mouse studies suggest intramuscular delivery of DNA vectors encoding human neutralizing antibodies could help prevent dengue fever and viral infections. A DNA vector was constructed containing IgG heavy...
BioCentury | Dec 9, 2013
Company News

PharmAthene, Theraclone deal

...month HHS's Biomedical Advanced Research and Development Authority (BARDA) said it did not select Theraclone's TCN-032...
...government funding and a significant worldwide market opportunity for one of Theraclone's most developed drugs. TCN-032...
...Kogyo Co. Ltd. (Tokyo, Japan) has exclusive, Japanese rights to Theraclone's influenza mAb program, which includes TCN-032...
BioCentury | Sep 16, 2013
Clinical News

Human anti-M2e antibody: Phase IIa data

...threshold for significance). Viral resistance analysis showed no change in the epitope recognized by TCN-032. TCN-032...
...Zenyaku, which supported the trial, has exclusive, Japanese rights to Theraclone's influenza mAb program, which includes TCN-032...
...Sciences Inc. , Seattle, Wash. Zenyaku Kogyo Co. Ltd. , Tokyo, Japan Product: Human anti-M2e antibody ( TCN-032...
BioCentury | Sep 10, 2013
Clinical News

Theraclone reports Phase IIa data for anti-flu mAb

...Theraclone Sciences Inc. (Seattle, Wash.) said a single dose of TCN-032 given 24 hours after viral...
...vs. placebo in a Phase IIa influenza A viral challenge trial (41.2% vs. 54.2%, p=0.21). TCN-032...
...in Cape Town. Next half, the company plans to start a Phase IIa trial of TCN-032...
BioCentury | Sep 9, 2013
Product Development

Viral persistence

...Theraclone Sciences Inc. was to present data Sept. 8 showing TCN-032 missed the primary endpoint in...
...of the Phase II program, with an initial focus on seriously ill hospitalized flu patients. TCN-032...
...24 hours later received a single dose of TCN-032 or placebo. On the primary endpoint, TCN-032...
BioCentury | Aug 5, 2013
Company News

PharmAthene, Theraclone deal

...advisor to Theraclone. The combined company's pipeline will include two Theraclone antibody products, TCN-202 and TCN-032...
...patients undergoing organ transplant surgery. A Phase II trial is slated to start this year. TCN-032...
...Kogyo Co. Ltd. (Tokyo, Japan) has exclusive, Japanese rights to Theraclone's influenza mAb program, which includes TCN-032...
BioCentury | Nov 5, 2012
Emerging Company Profile

Atreca: Sequencing B cells

...screens cells for activity prior to sequencing individual candidates. The company's most advanced candidate is TCN-032...
Items per page:
1 - 10 of 105